This small-cap biotech name could have further to run.
This small-cap biotech name could have further to run.

Biotech Just Got Trumped Real Money Pro($)

But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
This week's introduction of the NovaSeq Series of genomic sequencers caused the stock to jump.
Demographic trends that boosted big gains in prior years haven't gone away.
A one-day pullback wouldn't turn me into a bear.
The medical device company has been trading sideways for a long time and is likely to continue in the manner.
If prices continue higher they are likely to encounter resistance above $120.
The technical signs indicate the stage may be set for new highs in the maker of medical devices.

Columnist Conversations

See my Jan. 12, 2017 Real Money Pro article for details on my thought process regarding Chipotle Mexican Grill...
Right call by JPMorgan this morning. Stock has rallied off the December lows, propelled by signs CEO Steve Ell...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.